TORONTO, April 4 /CNW/ - Amorfix Life Sciences Ltd. reported today that
it has obtained the exclusive worldwide rights to additional novel targets on
Superoxide Dismutase-1 (SOD1), which is a protein known to misfold and
aggregate in the neurological disease Amyotrophic Lateral Sclerosis (ALS).
These new SOD1 targets broaden Amorfix's intellectual property estate on SOD1
and enhance its existing diagnostic and therapeutic strategies for the
treatment of ALS. The company also obtained an option to acquire the
intellectual property and know how surrounding the licensed technology.
